Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3258857 | 0.93 | — | — | |
| SCHEMBL23531396 | 0.87 | TDP1 (0.48) | TDP1HIF1APTGS1 | |
| SCHEMBL2558170 | 0.82 | — | — | |
| SCHEMBL23531274 | 0.82 | TDP1 (0.48) | TDP1HIF1APTGS1 | |
| SCHEMBL26703186 | 0.80 | TDP1 (0.53) | TDP1HIF1A | |
| SCHEMBL2423219 | 0.79 | — | — | |
| SCHEMBL672598 | 0.79 | TDP1 (0.53) | TDP1 | |
| SCHEMBL26127680 | 0.78 | — | — | |
| SCHEMBL10774489 | 0.76 | TSHR (0.54) | TDP1 | |
| SCHEMBL9770408 | 0.76 | TDP1 (0.53) | TDP1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023213922-A1 | PRECURSORS FOR THE CONTROLLED RELEASE OF α,β-UNSATURATED ALDEHYDES OR KETONES AND OTHER HIGH IMPACT FRAGRANCE SUBSTANCES | SYMRISE AG (DE) | 2023-11-09 | — | — | WO | disclosed |
| US-8629271-B2 | Compounds | ASTRAZENECA AB (GB) | 2014-01-14 | — | — | US | disclosed |
| US-20120322788-A1 | Compouds | PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) | 2012-12-20 | — | — | US | disclosed |
| EP-2242759-B1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8148373-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-04-03 | — | — | US | disclosed |
| CN-102083839-A | Compound (I) | ASTRAZENECA AB | 2011-06-01 | — | — | CN | disclosed |
| US-20090298807-A1 | Compounds | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322788-A1 | Compouds | PKD1, SBDS, ABCB11 | TDP1 4262/4885HIF1A 2232/4885PTGS1 329/4885 |
| US-20090298807-A1 | Compounds | PKD1, SLC10A1, ABCB11 | TDP1 4473/4885HIF1A 2703/4885PTGS1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.